-

Hims & Hers to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will report fourth quarter and full year 2022 financial results after the market closes on Monday, February 27, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.forhims.com and will be archived for one year.

Upcoming Conference Participation

Hims & Hers also announced that members of the company’s management team will be participating in the following upcoming investor conferences. All events will be webcast live and archived on the Hims & Hers investor relations website at https://investors.forhims.com.

  • Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 2, 2023 in New York City.
  • The JMP Securities Technology Conference on March 7, 2023 in San Francisco.
  • KeyBanc Emerging Technology Summit on March 8, 2023 in San Francisco.

About Hims & Hers Health, Inc.

Hims & Hers is a consumer-first platform transforming the way customers fulfill their health and wellness needs. Its digital platform enables access to treatments for a broad range of conditions, including those related to sexual health, hair loss, dermatology, mental health and primary care. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies on a subscription basis, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile apps, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Hims & Hers products can also be found in tens of thousands of top retail locations in the United States. Launched in November 2017, Hims & Hers serves the entire United States and select locations in the United Kingdom. The company is publicly traded on the New York Stock Exchange. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Contacts

Investor Relations
investors@forhims.com

Media Relations
press@forhims.com

Hims & Hers Health, Inc.

NYSE:HIMS

Release Versions

Contacts

Investor Relations
investors@forhims.com

Media Relations
press@forhims.com

More News From Hims & Hers Health, Inc.

Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company’s 2026 annual shareholder meeting in June. Amoo-Gottfried is a seasoned marketing leader with decades of experience helping global transformative brands change how consumers think about their everyday lives. He served as Chief Marketing Officer at DoorDash and in leadership roles at...

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenc...

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and deli...
Back to Newsroom